Kansas SB212: Enacting the prescription drug cost and affordability review act to establish the prescription drug pricing board and prescription drug affordability stakeholder council to review the cost of prescription medications and establish upper payment limits for certain prescription drugs

What the bill says

An act concerning health and healthcare; enacting the prescription drug cost and affordability review act; establishing the prescription drugs pricing board and prescription drug affordability stakeholder council to review the cost of prescription medications and establish upper payment limits for certain prescription drug products.

From the introduced text, February 5, 2025:

AN ACT concerning health and healthcare; enacting the prescription drug cost and affordability review act; establishing the prescription drugs pricing board and prescription drug affordability stakeholder council to review the cost of prescription medications and establish upper payment limits for certain prescription drug products. Be it enacted by the Legislature of the State of Kansas: Section 1. This act shall be known and may be cited as the prescription drug cost and affordability review act. Sec. 2. As used in sections 1 through 8, and amendments thereto: (a) "340B-covered entity" means an entity that is participating in the federal 340B drug pricing program authorized by 42 U.S.C. § 256b, including such entity's pharmacy or pharmacies, or any pharmacy or pharmacies contracted for the purpose of dispensing drugs purchased through such program. (b) "Biologic" means a drug that is produced or distributed in accordance with a biologics license application approved by the United States food and drug administration. (c) "Biosimilar" means a drug that is produced or distributed in accordance with a biologics license application approved under 42 U.S.C. § 262(k). (d) "Board" means the prescription drug affordability board created in section 3, and amendments thereto. (e) "Brand name drug" means a drug other than an authorized generic drug that is produced or distributed in accordance with an original new drug …

Read the full official text

Sponsors